mirtazapine has been researched along with Dyspepsia in 6 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Dyspepsia: Impaired digestion, especially after eating.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a randomized, placebo-controlled trial, mirtazapine significantly improved early satiation, quality of life, gastrointestinal-specific anxiety, nutrient tolerance, and weight loss in patients with FD." | 9.22 | Efficacy of Mirtazapine in Patients With Functional Dyspepsia and Weight Loss. ( Arts, J; Boeckxstaens, G; Caenepeel, P; Carbone, F; Holvoet, L; Ly, HG; Tack, J; Van Oudenhove, L; Vanheel, H; Vanuytsel, T, 2016) |
| "Mirtazapine not only alleviates symptoms associated with dyspepsia and depression linked to FD in patients with weight loss but also significantly increases body weight (mainly the visceral fat in body fat)." | 9.22 | Beneficial effects of antidepressant mirtazapine in functional dyspepsia patients with weight loss. ( Jia, L; Jiang, SM; Liu, J; Shi, MM; Xu, MZ, 2016) |
| "The objective of this study was to assess the clinical response and safety of mirtazapine in the pediatric population with a diagnosis of functional nausea and nausea associated with functional dyspepsia postprandial distress syndrome." | 8.12 | Effect of Mirtazapine on Nausea in Children with Functional Nausea and Functional Dyspepsia Postprandial Distress Syndrome. ( Hyman, PE; Iglesias-Escabi, IM; Kleesattel, D; LeBlanc, C; McDaniel, LS; Reuther, E; Santucci, NR, 2022) |
| "In a randomized, placebo-controlled trial, mirtazapine significantly improved early satiation, quality of life, gastrointestinal-specific anxiety, nutrient tolerance, and weight loss in patients with FD." | 5.22 | Efficacy of Mirtazapine in Patients With Functional Dyspepsia and Weight Loss. ( Arts, J; Boeckxstaens, G; Caenepeel, P; Carbone, F; Holvoet, L; Ly, HG; Tack, J; Van Oudenhove, L; Vanheel, H; Vanuytsel, T, 2016) |
| "Mirtazapine not only alleviates symptoms associated with dyspepsia and depression linked to FD in patients with weight loss but also significantly increases body weight (mainly the visceral fat in body fat)." | 5.22 | Beneficial effects of antidepressant mirtazapine in functional dyspepsia patients with weight loss. ( Jia, L; Jiang, SM; Liu, J; Shi, MM; Xu, MZ, 2016) |
| "The objective of this study was to assess the clinical response and safety of mirtazapine in the pediatric population with a diagnosis of functional nausea and nausea associated with functional dyspepsia postprandial distress syndrome." | 4.12 | Effect of Mirtazapine on Nausea in Children with Functional Nausea and Functional Dyspepsia Postprandial Distress Syndrome. ( Hyman, PE; Iglesias-Escabi, IM; Kleesattel, D; LeBlanc, C; McDaniel, LS; Reuther, E; Santucci, NR, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Iglesias-Escabi, IM | 1 |
| Kleesattel, D | 1 |
| McDaniel, LS | 1 |
| Reuther, E | 1 |
| LeBlanc, C | 1 |
| Hyman, PE | 1 |
| Santucci, NR | 1 |
| Luo, L | 1 |
| Du, L | 1 |
| Shen, J | 1 |
| Cen, M | 1 |
| Dai, N | 1 |
| Tack, J | 1 |
| Ly, HG | 1 |
| Carbone, F | 1 |
| Vanheel, H | 1 |
| Vanuytsel, T | 1 |
| Holvoet, L | 1 |
| Boeckxstaens, G | 1 |
| Caenepeel, P | 1 |
| Arts, J | 1 |
| Van Oudenhove, L | 1 |
| Jiang, SM | 1 |
| Jia, L | 1 |
| Liu, J | 1 |
| Shi, MM | 1 |
| Xu, MZ | 1 |
| Zimmermann-Viehoff, F | 1 |
| Bergander, B | 1 |
| Meissner, K | 1 |
| Deter, HC | 1 |
| Lee, SY | 1 |
| Rho, SH | 1 |
| Choi, SC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Short-term and Low-dose Application of Neuromodulators Increases Treatment Efficacy and Minimizes Antidepressant Discontinuation Syndrome in Refractory Functional Dyspepsia[NCT05099913] | 220 participants (Anticipated) | Interventional | 2020-08-01 | Recruiting | |||
| Phase 4 Study of Mirtazapine in Functional Dyspepsia Patients With Weight Loss[NCT01240096] | Phase 4 | 35 participants (Anticipated) | Interventional | 2006-09-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for mirtazapine and Dyspepsia
| Article | Year |
|---|---|
Efficacy of Mirtazapine in Patients With Functional Dyspepsia and Weight Loss.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Anxiety; Double-Blind Method; Dyspepsia; Female; Humans; | 2016 |
Beneficial effects of antidepressant mirtazapine in functional dyspepsia patients with weight loss.
Topics: Adiposity; Adult; Affect; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic | 2016 |
4 other studies available for mirtazapine and Dyspepsia
| Article | Year |
|---|---|
Effect of Mirtazapine on Nausea in Children with Functional Nausea and Functional Dyspepsia Postprandial Distress Syndrome.
Topics: Adolescent; Adult; Child; Depressive Disorder, Major; Dyspepsia; Female; Humans; Mirtazapine; Nausea | 2022 |
Benefit of small dose antidepressants for functional dyspepsia: Experience from a tertiary center in eastern China.
Topics: Anthracenes; Antidepressive Agents; China; Citalopram; Drug Combinations; Dyspepsia; Female; Fluoxet | 2019 |
[Integrative therapy of a patient with complex psychosomatic complaints].
Topics: Aged; Antidepressive Agents, Tricyclic; Depression; Dyspepsia; Female; Humans; Integrative Medicine; | 2008 |
Functional dyspepsia and mirtazapine.
Topics: Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Dyspepsia; Female; Humans; Limbic Syst | 2002 |